Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Blood (2022) 140 (Supplement 1): 4393–4395.

https://doi.org/10.1182/blood-2022-160071

Published: 2022

Journal Articles

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Manisha Bhutani, Myra Robinson, Barry Paul, Shebli Atrash, Cindy Varga, Xhevahire Begic, David M Foureau, Mauricio Pineda-Roman, Brinda Koya, Sarah Norek, Sara A Sutton, Michelle B Anderson, Donna Acampora, James T Symanowski, Peter M. Voorhees, Saad Usmani

Blood (2022) 140 (Supplement 1): 4440–4441.

https://doi.org/10.1182/blood-2022-160204

Published: 2022

Journal Articles

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Manisha Bhutani, MD, Monika House, RN, BA, Jiaxian He, MS, Shebli Atrash, David M Foureau, PhD, Barry Paul, MDMS, Reed Friend, MD, James T Symanowski, PhD, Sarah Norek, BSN, RN, Xhevahire Begic, MSPH, Donna Acampora, BSN, RN, Katherine K Farmer, BA, Carrie Ann Syfert, BSN, RN, Mauricio Pineda-Roman, MD, Peter Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-138485

Published: 2020